All authors listed in a manuscript submitted to Beijing Da Xue Xue Bao Yi Xue Ban must have contributed substantially to the work. Upon submission of the manuscript, the corresponding author must indicate, in the online submission and in the Authorship section of the manuscript, the specific contribution of each author. Examples of appropriate designations include: designed research, performed research, contributed vital new reagents or analytical tools, collected data, analyzed and interpreted data, performed statistical analysis, and/or wrote the manuscript. An author may list more than one type of contribution and more than one author may have contributed to the same aspect of the work. The corresponding author assumes responsibility for obtaining permission from all coauthors for the submission of any/all version(s) of the manuscript and for any changes in authorship.
If a manuscript reports on the results of a clinical trial run by a study group or collaborative clinical trials network, those members who meet criteria for authorship should be listed individually in the byline. For studies with a large number of authors, the journal reserves the right to request creation of a study group before publication. The corresponding author may be contacted by the Beijing Da Xue Xue Bao Yi Xue Ban office in such cases. In your correspondence, please clearly define the role of each author according to this criteria.
If authorship is attributed to a group listed as author (e.g., only the group name is in the byline or in addition to one or more individual authors), all members of the group must meet the full criteria and requirements for authorship as described above and they are acknowledged as authors in Medline. The group members who do not meet the formal authorship criteria listed above but who contributed materially as collaborators may be named in the Appendix and if the manuscript is accepted, their names will be listed in an online supplemental Appendix. The group members listed in Acknowledgments or in the Appendix are acknowledged as collaborators in Medline/PubMed.
All individuals share responsibility for any manuscript they coauthor. Some coauthors have responsibility for the entire manuscript as an accurate, verifiable report of the research. These include coauthors accountable for the conception or execution of the research reported in the paper, the integrity and analysis of the data, or the writing of the manuscript. Coauthors with specific, limited contributions to a paper are responsible for their contributions but may have only limited responsibility for other results. While not all coauthors may be familiar with all aspects of the research presented in the manuscript, all coauthors should have in place an appropriate process for reviewing the accuracy of the reported results. Each author should review and approve the manuscript before publication. The corresponding author is responsible for the integrity of the work as a whole.
For more information on this important topic, see the Authorship section in the CSE’s White Paper on Promoting Integrity in Scientific Journal Publications.
Conflict of interest disclosure
Beijing Da Xue Xue Bao Yi Xue Ban is committed to ensuring the integrity of all their activities. The conflict of interest disclosure policy for Beijing Da Xue Xue Bao Yi Xue Ban contributors requires each author to disclose all relevant financial and other interests, regardless of amount or value, which might be construed as resulting in an actual, potential, or apparent conflict in one’s role as contributor to Beijing Da Xue Xue Bao Yi Xue Ban.
At the time of submission to Beijing Da Xue Xue Bao Yi Xue Ban, authors are required to disclose any potential conflict of interest, which may include one or more of the following: employment; consultancy within the past two years; ownership interests (including stock options) in a start-up company, the stock of which is not publicly traded; ownership interest (including stock options but excluding indirect investments through mutual funds and the like) in a publicly traded company; research funding; honoraria received directly from an entity; paid expert testimony within the past two years; any other potential financial relationship (e.g., holding a patent or receiving royalties); and/or membership on another entity’s Board of Directors or its advisory committees (whether for profit or not for profit).
Any involvement by pharmaceutical or medical device company employees or medical writers supported by a pharmaceutical or medical device company in the writing of an article must be clearly defined and disclosed in the Conflict-of-Interest Disclosure section of the manuscript (if the individual is an author) or the Acknowledgments section (if the individual is not an author).
For Review Articles and Beijing Da Xue Xue Bao Yi Xue Ban Talks: Pharmaceutical or medical device company employees and medical writers supported by a pharmaceutical or medical device company are not permitted to have any role in writing these articles. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.
If the authors have no conflict of interest to declare, they must state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and to collectively list ALL pertinent commercial relationships in the manuscript (under the Acknowledgment section or in the Authorship section) and in the metadata of the online submission.
It is important to note that this policy and the disclosure statements will not be regarded as creating a presumption of impropriety in the existence of financial interests or other relationships of a commercial nature. Instead Beijing Da Xue Xue Bao Yi Xue Ban’ purpose is to inform its editors, reviewers, and readers of the existence of financial relationships pertinent to the article in the interest of full transparency in the peer review and publication processes.
During the peer review process any conflicts of interest will be disclosed only to editors and reviewers, who will keep them confidential. If the paper is accepted for publication in Beijing Da Xue Xue Bao Yi Xue Ban, all disclosures, including statements of no conflict of interest, will appear in published article, in the Authorship section.
Upon acceptance, all authors are asked to sign their copyright transfer, which is available to all authors upon successful initial submission and requires authors to confirm that any relevant conflicts of interest are disclosed in the manuscript. An article will not be published in the journal until all signatures are received.
Beijing Da Xue Xue Bao Yi Xue Ban accepts only manuscripts that describe original work. Special cases regarding manuscripts expanding upon meeting abstracts and manuscripts with preprints are listed below. Copies of existing manuscripts with overlapping or duplicated material should be submitted together with the manuscript as supplemental data files so that the Editors can judge the originality of the material and its suitability for publication. Submission of duplicate content, already published elsewhere, will be considered a breach of ethical conduct and will trigger severe consequences.
Manuscripts related to published meeting abstracts
Manuscripts containing material that was previously presented as a digital poster presented in a conference or meeting with an online poster repository or videotaped will be considered for publication in Beijing Da Xue Xue Bao Yi Xue Ban if significant new information is included.
Principles for publication of medical research involving human subjects
All studies that involve human subjects must abide by the rules of the appropriate institutional review board (or equivalent organization) of the institution in which the research was conducted and by the tenets of the World Medical Association’s most recently revised Declaration of Helsinki. A statement regarding ethical approval and Helsinki compliance must be included in the Methods section of the paper.
Published studies that involve human subjects should not provide subjects’ identifying information (e.g., names, true initials, recognizable images) unless the information is essential for scientific purposes and the patient (or the patient’s parent/guardian) gives written informed consent for publication. If your study requires the appropriate written consent, please send a statement to firstname.lastname@example.org affirming that you possess the patient’s written consent. See the Uniform Requirements for Manuscripts Submitted to Biomedical Journals for further information.
All studies using animals should follow the ARRIVE guidelines for reporting in vivo experiments in animal research. A statement regarding institutional animal care and use committee approval (or equivalent) must be included in the Methods section of the paper.
Clinical trial reporting and registry
Beijing Da Xue Xue Bao Yi Xue Ban welcomes submission of manuscripts reporting on clinical trials whether phase 1, 2, 3 or 4. Reports should include a full description of the study design, patient population, methodology and conduct, and statistical plan. In all cases, the report will undergo peer review and will be evaluated for technical merit, novelty, clinical and scientific impact, and other measures to determine suitability for publication.
As defined by the International Committee of Medical Journal Editors (ICMJE), a clinical trial is ‘any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome’.
Beijing Da Xue Xue Bao Yi Xue Ban follows the trial registration policy of the ICMJE and considers only trials that have been registered before submission, and before the onset of patient enrollment. Acceptable registries must be ICMJE-approved (see more information in the section below).
For authors reporting phase II and phase III randomized controlled trials it is recommended to consult the CONSORT Statement and Checklist to facilitate the complete and transparent reporting of trial findings. In addition, including a Patient Flow Diagram in the manuscript is recommended for randomized studies.
Registration number and name of the trial registry must be provided at the end of the article abstract.
In accordance with the guidelines published by the International Committee of Medical Journal Editors (ICMJE), Beijing Da Xue Xue Bao Yi Xue Ban requires, as a condition of consideration for publication, that all clinical trials be registered in any of the primary registers that participate in the WHO International Clinical Trial Registry Platform (ICTRP) or in ClinicalTrials.gov. (See full list here). Trials must be registered at or before the onset of patient enrollment.
In addition to accepting registration in any of the above five registries, Beijing Da Xue Xue Bao Yi Xue Ban will accept registration of clinical trials in any of the primary registers that participate in the WHO International Clinical Trial Registry Platform (ICTRP) or in EudraCT. Registration in a partner register only is insufficient.
Following ICMJE, Beijing Da Xue Xue Bao Yi Xue Ban will not consider results posted in the same clinical trials registry in which the primary registration resides to be previous publication if the results are presented in the form of a brief (< 500 words), structured abstract or table.
For more information, see the ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals.
WeChat public address
Sponsor: Peking University
Editor-in-Chief: ZHAN Qi-min
Executive Editor-in-Chief: ZENG Gui-fang
Editing and Publishing: Editorial Department of Journal of Peking University (Health Sciences)